Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis

Wyeth

Status and phase: Completed; Phase 4

Conditions: Psoriasis

Treatments: Drug: Etanercept

Study type: Interventional

Funder types: Industry

Identifiers

NCT00195507

0881A6-101764

Details and patient eligibility

About

This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis.

Enrollment: 720 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stable, active plaque psoriasis
• Failure to respond to the following systemic therapies: Methotrexate, Cyclosporine, PUVA or Fumarate

Exclusion criteria

• Evidence of skin conditions other than psoriasis that would interfere with evaluations of the effect of the study
• Systemic psoriasis therapy within 28 days prior

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)